Almirall, Etherna Partner to Develop mRNA-based Therapies in Medical Dermatology
Almirall, S.A. (ALM) and etherna are teaming up to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The alliance combines and leverages etherna’s proprietary mRNA capabilities and lipid nanoparticle (LNP) formulations with Almirall’s medical dermatology expertise to accelerate discovery of novel treatment options. Etherna and Almirall will work collaboratively on the research […]
New Drugs: Oleogel-S10 for Epidermolysis Bullosa
Dr. Ted Rosen discusses the investigational drug oleogel-S10 for epidermolysis bullosa. Ted Rosen, MD, FAAD Professor of Dermatology, Baylor College of Medicine, Houston, Texas Oleogel-S10 (Filsuvez, Amryt) is under consideration by the FDA and approved in the European Union (EU) and Great Britain for the treatment of partial thickness wounds associated with junctional and dystrophic epidermolysis bullosa in […]
New Drugs: Deucravacitinib for Plaque Psoriasis
Dr. Ted Rosen reports on the FDA’s recent approval of deucravacitinib, the first drug in its class for treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy and phototherapy. Ted Rosen, MD, FAAD Editor-in-Chief As the first drug in its class, deucravacitinib (Sotyktu, Bristol Myers Squibb) has received FDA […]
New Drugs: Opdualag
A Dual Immunotherapy for Metastatic Melanoma By Ted Rosen, MD Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab to treat adult and pediatric patients with unresectable or metastatic melanoma. The FDA recently approved a dual immunotherapy drug for the treatment of adult and pediatric patients […]